[Frontiers in Bioscience 7, d442-457, Feburary 1, 2002]


Hongwei Yu and Nathan E. Head

Department of Microbiology, Immunology and Molecular Genetics, Joan C. Edwards School of Medicine at Marshall University, 1542 Spring Valley Drive, Huntington, WV 25704


1. Abstract
2. Cystic fibrosis
3. P. aeruginosa
4. Chronic infection phenotypes: biofilm and mucoidy
5. Genetic diversity and genomic islands
6. Aerosol infection mouse model
7. Persistent infection phenotype and immunity
8. Future challenges
9. Acknowledgements
10. References


Cystic fibrosis (CF) is the most common autosomal recessive lethal disease in the Caucasian population. Chronic respiratory infections with Pseudomonas aeruginosa, neutrophil-dominated airway inflammation and progressive lung damage are the major causes of morbidity and mortality in CF. Two persistent infection phenotypes expressed by this bacterium are biofilm and mucoidy. Biofilm, also called the microcolony mode of growth is the surface-associated adherent bacterial community, while mucoidy refers to a phenotype conducive to copious amounts of mucoid exopolysaccharide (MEP)/alginate that provides a matrix for mature biofilms conferring resistance to host defenses and antibiotics. Recent completion of the whole genomic sequence of the standard reference strain P. aeruginosa PAO1 has led to discoveries that many clinical isolates of this species possess unique genomic sequences (genomic islands) due to horizontal gene transfer. We propose this type of genetic exchange may play an important role in causing intrinsic genomic diversity of this organism. Therefore, the diversity, as revealed through profiles of restriction fragment length polymorphism (RFLP), may be linked to an array of novel and unexplored pathogenic mechanisms in P. aeruginosa. CF mouse models, while displaying many clinical similarities to human CF, have yet to demonstrate a chronic pulmonary disease phenotype. This review is intended to provide an overview of P. aeruginosa persistent infection phenotypes (biofilm and mucoidy) and an aerosol infection mouse model for CF. Genomic diversity of P. aeruginosa and its implications in the pathogenesis in CF will also be discussed.


Approximately 30,000 children and adults in the United States have CF. One in 31 Americans, more than 10 million people are asymptomatic carriers of the mutant CF gene. Despite many promising advances in CF medicine, the median life expectancy for CF patients is 30 years (1). Like other genetic diseases, the predisposing factor is a mutation of an otherwise functional gene. The CF gene has been identified, and the gene product is named the CF transmembrane conductance regulator (CFTR) (2). Since the initial discovery, close to 1,000 different types of disease-causing mutations within this gene have been documented (http://www.genet.sickkids.on.ca/). By far the most common, which accounts for almost 70% of all known mutations is a three base pair deletion resulting in the removal of a phenylalanine residue at position 508 of CFTR (deltaF508).

CFTR is a multifunctional protein located on the apical plasma membrane. It is an anion channel and/or a channel regulator that controls the flow of Cl-, Na+ and other ions across the membrane. Defects in CFTR result in disruption of normal Na+ and Cl- ion transport (3). Recently, CFTR has been linked with the control of Cl--coupled bicarbonate concentration across the lumen of the lung epithelium for maintaining the proper acidity (4). The cellular defects associated with the CFTR mutations cause many clinical problems, but the majority are confined to those organs rich in exocrine glands such as respiratory, gastrointestinal and genitourinary tracts (5). Approximately 85% of CF patients are characterized with pancreatic insufficiency (PI) while 10-15% of them have a clinical condition called meconium ileus (MI), an intestinal blockage due to malabsorption (6). Patients homozygous for the deltaF508 mutation tend to have more severe pancreatic insufficiency than those carrying other types of mutations (6). Conditions such as vitamin deficiency (A, D, E and K) and chronic malnutrition are common in CF (7). The clinical manifestation of CF is mainly demonstrated through involvement of the respiratory tracts. The electrolytic imbalance combined with acidic pH due to defective bicarbonate transport results in changes in the composition of airway surface liquid (ASL), a thin layer of fluid that covers the upper and lower respiratory tract, and retention of an abnormal dehydrated viscous mucous within the lung (4). These conditions leave the CF lungs prone to becoming infected with microbial organisms (8).

Pulmonary infections in CF are associated with chronic colonization by several bacterial pathogens and debilitating exacerbations as a result of bacterial and viral infections superimposed upon progressive lung damage (9). Children with CF are often infected by Staphylococcus aureus and Haemophilus influenzae, both within the patient's first 3 years (10). Since the development of aggressive antibiotic therapy, these organisms can be treated before any long-term damage is inflicted. While both S. aureus and H. influenzae will re-emerge in the lung throughout the remainder of the disease, P. aeruginosa ultimately becomes the major inhabitant for the remainder of the CF patient's life (9). In fact, nearly all CF patients will show evidence of P. aeruginosa colonizations by age 3 (11). Chronic lung infections with P. aeruginosa are responsible for the majority of early deaths in CF (12).

Though CF biogenesis is clear, the relationship between CFTR mutations and pulmonary disease is elusive. Particularly, how the genetic defect leads to the establishment of chronic bacterial colonization in the lungs is not fully understood. Several concurrent and sometimes conflicting proposals have been offered (13-18) to address this relationship. For example, reduced sialylation of glycoconjugates on the surface of epithelial cells has been suggested to promote P. aeruginosa adhesion in CF (18). However, a recent paper has questioned the role of this glycolipid as the receptor for fresh clinical isolates of P. aeruginosa since the antibodies raised against asialo-GM1 for confirming its interaction with P. aeruginosa also bind to multiple P. aeruginosa surface antigens (19).

The CF epithelial secretions have been reported to display reduced bactericidal properties due to the altered salt content (14, 17). CFTR has also been proposed to be involved in P. aeruginosa uptake by respiratory epithelial cells (16). These models rely mainly on the known functions of CFTR as an ion channel and/or channel regulator (6) and on its presumed pleiotropic effects (20). Other studies, focusing on cytokine profiles in broncho-alveolar lavage fluids of CF patients, have suggested that the propensity for excessive inflammation in CF may be attributed to endogenously increased levels of proinflammatory cytokines such as tumor necrosis factor (TNF)-alpha, interleukin (IL)-8, and IL-1 (13), and concurrent decreased level of anti-inflammatory cytokine IL-10 (105). According to some reports, the levels of these cytokines may be altered in CF even before a bacterial infection begins (15, 21). Despite these promising leads, our understanding of host-pathogen interactions in CF is minimal. Even though the most obvious physiological defect in CF is linked with ion transport, pathological consequences due to a CFTR mutation appear to be more complex.


P. aeruginosa is a ubiquitous Gram-negative environmental bacterium that can grow in a wide variety of moist habitats such as soil, rivers, hospital sinks and oil fields and has an extremely versatile metabolic demand. This organism can colonize humans, invertebrates, insects, and plants. It is considered an opportunistic pathogen since the infections only occur in individuals with underlying compromised host defense systems (22). Besides being associated with fatal pneumonia in CF, P. aeruginosa can cause other types of infections ranging from acute and systemic bacterimia to chronic catcher-associated urinary tract infections (8).

The genome of the P. aeruginosa strain PAO1 has recently been completely sequenced and released to the public domain (http://www.pseudomonas.com/) (figure 1 and ref. 23). A quick comparison of this genome to a selected group of bacterial genomes is listed in table 1. The genome size of P. aeruginosa is the largest among the currently available pathogenic bacteria in GenBank, and has a coding capacity for 5,570 open reading frames (ORF's; ref. 23). Initial analysis of the PAO1 genome suggests the overall gene regulation is more complicated than that of the E. coli strain MG1655. For example, the number of the two-component signal transduction systems in PAO1 is 144 (23 per Mb) whereas that of E. coli is only 62 (13 per Mb; ref. 23). The inherent drug resistance of this pathogen can be in part attributed to the increased number of efflux pumps encoded within the genome (97). The P. aeruginosa strain PAO1 was originally isolated from a wound (24), and is considered a standard reference strain well adapted to the laboratory growth conditions. The O5 serotype to which PAO1 belongs represents a small fraction (2.5%) of the clinical CF isolates surveyed during the late 1980's (personal communication with Dr. Joseph Lam). According to the pulsed-field gel electrophoresis (PFGE) analysis, the genomic profile of PAO1 is not similar to that of the majority of the clinical CF isolates. Therefore, it is unclear how representative this genome is compared to those of clinical isolates since the number of mobile genetic elements (genomic islands, phages and transposons) within each genome of clinical origin remains unknown.


In response to changing environments, microorganisms have evolved various adaptive mechanisms and as a result they often express different phenotypes. Bacterial biofilms are one of the persistent infection phenotypes (1). P. aeruginosa biofilms and CF chronic pulmonary infections are closely related (25, 26). Biofilm is often defined as exopolysaccharide-surrounded bacteria, or microcolonies, growing on biotic or abiotic surfaces (27). Formation of biofilms has been shown to be the preferred mode of bacterial growth in nature as the sessile population exceeds that of planktonic (free floating) biomass by 2-4 log10 units (28). The two modes of growth complement each other; the mobile phase provides a means for spread and colonization, while the biofilms afford protection against protozoans, phages, and antibiotics in environments (28).

Biofilm formation is a dynamic and complex process that can be roughly divided into four phases (1): i) initial attachment to the surface (transition from planktonic cells to transiently attached cells); ii) cell proliferation forming a monolayer; iii) formation of a microcolony; and iv) development of mature biofilms. In terms of biofilm formation within the CF lungs, it is still not fully understood how this process is initiated. Even so, a hypothetical and perhaps oversimplified scheme is presented in figure 2. Based on several studies monitoring biofilm formation on abiotic surfaces, motility is important for the initial attachment to the surface since it provides the forces required to overcome the surface repulsion for bacteria (29). Type IV pili mutant of P. aeruginosa forms thin and undifferentiated monolayers, but fails to differentiate into microcolonies (30). Other factors may also be required since a hyperpiliated P. aeruginosa strain without twitching ability is still able to form thick biofilms (31). Some surface-associated proteins such as curli and outer membrane proteins (32) also play a role in the initial attachment. Very recently, through screening the Tn5 insertion library for surface adhesion deficiency in the type IV pili mutant background of P. aeruginosa PAK, Vallet et al. (33) reported the identification of a novel chaperone/usher pathway involved in the assembly of new classes of adhesins that are needed for early biofilm formation, suggesting that multiple adhesion factors are present on the cell surface of P. aeruginosa. Furthermore, many global regulators such as the crc gene involved in carbon metabolism (34) and polyphosphate kinase (35), and more recently, a two-component regulatory system GacA/GacS (36), are also known to participate in the initial biofilm formation.

After initial attachment, P. aeruginosa biofilm formation requires participation of a cell density-dependent response, known as quorum sensing consisting of two distinct but interrelated systems, las and rhl (37). These

systems work coordinately to regulate a number of factors that enable this pathogen to survive in highly diverse environments. Two molecules produced are N-(3-oxododecanoyl)-L-homoserine lactone (3OC12-HSL) and N-butyryl-L-HSL (C4-HSL), which serve as signals for regulation of the cell-to-cell communication (38, 39). Particularly, 3OC12-HSL is involved in microcolony differentiation (40). Recently, using a sensitive radiometric assay coupled with a reverse phase high performance liquid chromatography to directly measure the level of acyl-HSLs, Singh et al. (26) reported that CF sputum carrying P. aeruginosa has more C4-HSL than 3OC12-HSL, which is similar to PAO1 grown in the biofilm mode, suggesting that C4-HSL may serve as a biomarker for mature biofilms (figure 2). Although alginate helps to maintain three dimensional structure of biofilms, alginate per se does not appear to be required for the initial P. aeruginosa biofilm development (31, 41). Furthermore, the wild type and lasI mutant of PAO1 produce an equal amount of alginate when forming biofilm in vitro (40). This appears to support the notion that control of alginate production is independent of at least 3OC12-HSL mediated quorum sensing pathway. Therefore, the initial biofilm formation and MEP based biofilms may represent two separate phenomena and/or two different stages of biofilm development. To distinguish the initial biofilm formation from those microcolonies embedded with a mucoid coat as commonly seen in CF, we introduce a term called "mature" biofilms to describe those covered with excessive amounts of alginate (figures 2 and 4).

The major component of the mucoid capsule produced by P. aeruginosa is alginate that consists of negatively-charged polyuronic acid (9). During chronic respiratory tract colonization, a subset of initial nonmucoid colonizing P. aeruginosa strains may acquire mutations causing conversion to mucoidy (42). The transition from the initial non-mucoid strain to the mucoid variant has recently been reproduced in vitro with repeated exposure to a sublethal concentration of hydrogen peroxide, a common oxidant in polymorphonuclear neutrophils (PMN's) (43). Overproduction of alginate in P. aeruginosa facilitates development of mature biofilms that contribute to immune evasion and antibiotic resistance (figures 2 and 4) (1). This unique phenotype (figure 3) is the main diagnostic indicator for the chronic onset of Pseudomonas lung infections in CF (44). The mucoid phenotype is usually unstable, but it is possible to maintain this phenotype in vitro using certain

laboratory media (figure 3). Mucoidy is of importance to the persistence of P. aeruginosa in CF. Protective, opsonizing antibodies against alginate are present only in uncolonized patients (45). The mucoid variant can influence the pulmonary outcome in CF patients (46). Alginate also has other pathogenic roles such as inhibition of phagocytosis, suppression of neutrophil chemotaxis, and scavenging of oxidative radicals (9).

Persistence of P. aeruginosa and mucoidy are two inseparable clinical conditions since emergence of mucoid phenotype in CF-affected lungs correlates with onset of pulmonary function deterioration (47). One of the molecular mechanisms related to mucoidy conversion is up-regulation of an alternative sigma factor (AlgU/AlgT) that in turn activates expression of algD, the biosynthetic gene for alginate production (48). AlgU, a stress-related sigma factor with extracytoplasmic function (ECF), is negatively regulated by its immediate downstream gene cluster, mucABCD where MucA is the cognate antisigma factor for AlgU (48). The AlgU ortholog in E. coli is RpoE (sigmaE) (66% identity and 91% overall similarity). The E. coli rpoE gene can functionally complement the algU mutation and restore mucoidy in P. aeruginosa (49). Furthermore, up-regulation of algU inhibits flagellum synthesis (50). Recently, we have found that inactivation of algU and rpoE in P. aeruginosa PAO1 and E. coli K12, respectively, could lead to increased flagellar activity in both organisms, thereby causing increased initial biofilm formation in vitro and in vivo (51). Conversely, overproduction of sigmaE in E. coli K12 causes reduced initial biofilm formation (51). This is interesting since an earlier report indicates that inactivation of algU in PAO1 caused increased virulence in a systemic infection mouse model (52). This elevated virulence as a result of algU inactivation may be due to increased initial colonization of the mutant. Two recent analyses using proteomics to compare global protein expression coupled with mucoidy indicate that production of several proteins such as outer membrane protein porin F (OprF) and disulfide bond isomerase (DsbA), which may not be involved in alginate production, is affected (53, 54). These candidates may play a role in induction of mucoidy-coupled host-derived human beta-defensin (55). As a result of the bioinformatic analysis of the PAO1 genomic sequence, three additional genetic loci in this genome (figure 1) have been proposed to be involved in production of exopolysaccharide in P. aeruginosa (23). It will be interesting to investigate if any of these genes may indeed be required for alginate regulation since there is an alternative AlgU-independent pathway that involves RpoN (sigma54) for the control of MEP production (56).


The genomes of the clinical CF and environmental isolates (figure 5) of P. aeruginosa are highly polymorphic. This phenomenon is also referred to as genomic diversity (57-59). From an evolutionary viewpoint, genomic diversity enhances metabolic versatility of the organism. To investigate the diversity, a DNA scoring method is often used, which depends on macrorestriction digestion of the chromosome coupled with physical separation of DNA fragments in a PFGE system (60). The distinctive banding pattern generated in this system, known as RFLP (figure 5), represents a unique genetic fingerprint and once assembled, reflects the overall genomic structure of each isolate. Besides being used for investigation into the diversity (57-59, 61), the P. aeruginosa RFLP profiles coupled with linkage analysis have been applied towards construction of a genomic map (62-65), comparative genomic analysis (66), and investigation of genetic differences among clinical isolates (67). The RFLP profiles have also been utilized for epidemiological analysis to track the sources of clinical isolates (68-70). Another common DNA scoring technique, based on the polymerase chain reaction (PCR), is random amplification of polymorphic DNA (RAPD) which has been applied for a similar purpose (71, 72). While these methods provide a quick means to generate genomic comparison, they are often limited by lack of information on individual DNA fragments produced within these systems.

The availability of the PAO1 genomic sequence facilitates utilization of PFGE more effectively to study genomic diversity among various clinical isolates. For example, it has been previously reported that complete digestion of the PAO1 genome with restriction endonuclease SpeI generated 37 fragments in a PFGE system (64). While the estimation of fragment sizes was not always accurate, one can deduce a precise range of fragments based on the PAO1 genomic sequence. These bands, listed in table 2, may be used as a standard reference for comparison with clinical CF isolates. In our initial PFGE analysis of 101 clinical CF isolates, which were collected over a wide range of geographical regions and compared with the standard banding pattern of PAO1 (table 2), we identified 75 unique SpeI-digested genomic profiles with 23�12 bands (n = 75; 99% confidence interval; ref. 73). Of these isolates, 51% have at least one band significantly larger than the largest fragment of PAO1 (Spe-A = 539,862 bp). We observed 74% genomic diversity among the CF isolates in our collection. This number perhaps under-estimates the genomic diversity of P. aeruginosa since the remaining 26% non-unique genomic profiles were sequential, sibling or same-source isolates. It appears that a particular isolate remains fairly stable in its genome after it colonizes the CF lung (figure 5), which is consistent with a previous observation that the majority of CF patients are colonized with one strain (74). However it is possible for a single patient to be colonized by 2 different strains at the same time (71, 74). Horizontal transmission between patients is possible since identical genomic profiles have been seen between CF isolates and an isolate from aquatic habitats (59, 66).

The ultimate cause of genomic diversity that exists throughout clinical CF isolates of P. aeruginosa is attributed to mutation (75). One of the virulence mechanisms employed by many pathogenic bacteria is the acquisition of auxiliary DNA sequences from within or between species or even genera (76). There is compelling evidence to suggest that the event of horizontal gene transfer occurs in P. aeruginosa (77-79). Mobile genetic elements such as bacterial phages are probably present in the PAO1 genome (figure 1 and ref. 23). Some of the Pseudomonas phages have the genetic capacity of serotype conversion (80). Tummler et al. (66) were among the first to notice that the genome of one aquatic/CF isolate of P. aeruginosa was significantly larger than that of PAO1. A subsequent study with a clinical wound isolate of P. aeruginosa, UCBPP-PA14 (PA14), has reported the discovery of several unique chromosomal regions found in this strain but not present in the PAO1 genome (81-83).

Recently, Liang et al. (78) have reported the identification of the first genomic island (PAGI-1; figure 1), in the genome of a clinical urinary tract infection isolate P. aeruginosa X24509. This genetic island is absent in PAO1, but is present in 85% of the clinical isolates including those from CF patients. It is composed of 48,893 bp with a coding capacity for 51 ORF's. Through recombination, this island replaces a region of 6,729 bp sequence derived from the PAO1 genome that is thought to be prone to genetic alterations. Interestingly, this PAGI-1-replaced locus is located within a previously identified region with unusually low G+C content (PA2221-PA2228, G+C: 49.2% vs. 66.6% overall; figure 1) (23). While the functions of PAGI-1 need to be elucidated, there are at least two potential transcriptional regulators located on the island, one of which is the homologue of RpoN-dependent transcriptional activators. Furthermore, two homologs of E. coli, which are known to be involved in counteracting oxidative stress, are also encoded on PAGI-1. Since RpoN has been implicated in the regulation of mucoidy (56) and other surface molecules such as flagella and pili, it is conceivable that some genes encoded on PAGI-1 may have specific virulence roles including modulation of chronic infection phenotypes.

The discovery of PAGI-1 suggests that an island of this nature may contribute to causing the genomic diversity observed with PFGE. For example, within the PAGI-1 DNA sequence (GenBank accession# AF241171), there are five positions recognizable by endonucleases SpeI and XbaI (4 sites) that are often used for PFGE analysis of P. aeruginosa genomes. Therefore, a genomic island is linked with a cause of genomic diversity of P. aeruginosa. A recent publication of the E. coli O157:H7 genome sequence indicates that this virulent strain, unlike the laboratory counterpart E. coli K12, has an additional 1.34 Mb encoding 1,387 new genes in 177 O157:H7-specific genomic islands interspersed in a K12 genome (84). Based on the overall sequence homology between P. aeruginosa PAO1 and E. coli K12 (23), it is reasonable to assume that more genomic islands are to be identified throughout the P. aeruginosa genomes. It is known that severity of the pulmonary disease in CF is poorly correlated with the genotype (6). This variability can be attributed to many factors of environmental and/or host origin. Perhaps it can also be caused by factors of bacterial origin through the diversity. Genomic diversity resulting from horizontal gene transfer suggests a possibility of acquisition of novel virulence traits in P. aeruginosa. For example, flagella of some P. aeruginosa strains are often glycosylated (85). Very recently, it has been reported (77) that another genomic island of ca. 16 kb located immediately upstream of the fliC gene encoding the structural flagellin protein is responsible for this action. Although the pathogenic significance of this glycosylation is still unknown, this discovery may become the first example demonstrating that horizontal gene transfer introduces a novel virulence mechanism into this organism.


An appropriate animal model is essential for simulating the respiratory tract infection in CF. The availability of CFTR transgenic mice has enabled us to investigate CF-related bacterial pulmonary infections in a surrogate host. Currently, there are several genetic mouse models for CF (86-93). These CF mice, while displaying several similar characteristics of intestinal disease in human CF, fail to develop respiratory infections or other signs of overt lung disease. This disappointing limitation of the CFTR transgenic mice, has been linked to the presence of alternative Cl- and Na+ channels in mice that could compensate for the loss of the CFTR lesion (94). No apparent differences in the ionic compositions of ASL have been found between CFTR mutant mice and their littermate controls (95). With the recent development of sensitive methods to directly measure the contents of ASL such as the use of a cryoprobe (96) and staining with fluorescent ion indicators (97), there is still no significant difference in ASL salt content between wild type and CF mice. More importantly, spontaneous colonization with P. aeruginosa has not been detected in the CF animals (98). While there are numerous mouse infection models for CF, each model has its pros and cons (8, 99). For example, the agar-bead model, in which P. aeruginosa is artificially embedded in agar beads, simulates a situation similar to mature biofilm infection. On the other hand, the aerosol infection model described below may be more useful in modeling the innate host response immediately after initial Pseudomonas colonization.

A Bacterial Aerosol Induced Lung Infection (BAILI) mouse model has been developed for simulation of bacterial pulmonary infections in CF (100-102). This model utilizes the aerosol technology originally developed for tuberculosis studies (103). The core of this model is an

inhalation exposure system where artificially generated P. aeruginosa aerosols are evenly introduced to murine lungs within the system (figure 6A and 6B). This apparatus, which has also been described elsewhere (8), has a nebulizer-Venturi unit into which a bacterial suspension is introduced (figure 6B). Pseudomonas suspension is atomized and mixed with room air, and this cloud of bacterial aerosol is introduced into the chamber. The whole system is negatively pressurized with a microprocessor to control cycles of preheating, nebulizing, exposure, and bacterial cloudy decay. The exhaust air is passed through a HEPA filter and an incinerator in the rear of the unit

(figure 6B). Two built-in bactericidal UV lamps within the system are used at the cycle end for chamber decontamination. Using this model, the following mice have been tested for respiratory tract infections, based on a regimen of single (innate) and repeated (chronic) exposures to P. aeruginosa aerosols, and investigated for bacterial clearance and inflammatory responses. These mice include C57BL/6J, BALB/cJ, DBA, IL-10 and TNF-alpha knockout mice (100-102).

The wild type C57BL/6J mice were first tested for single and multiple exposures in this BAILI model (101). While a single exposure to P. aeruginosa aerosol resulted in only mild histopathological changes, repeated exposures caused significant lung pathology in C57BL/6J mice. Mucoid cells (mucA22) were cleared several-fold less efficiently than isogenic nonmucoid (mucA+) cells during the initial stages of aerosol exposure. However, microscopic pathology findings and proinflammatory cytokine levels were similar in mice exposed to nonmucoid and mucoid P. aeruginosa throughout the infection. Lung histopathology and proinflammatory cytokines were tested in IL-10 deficient transgenic mice (IL-10T). Significant mortality was seen in the IL-10T mice on initial challenge with P. aeruginosa. Increased pathology was detected upon repeated challenge with P. aeruginosa in the IL-10T mice relative to the C57BL/6J mice. In an chronic infection agar-bead model with IL-10 knockout mice, a similar finding was noted (104). These observations suggest that anti-inflammatory cytokines may play a role in suppressing P. aeruginosa-induced tissue damage during chronic infection, and that reduced IL-10 levels in the lungs of CF patients (105) may be of significance for the respiratory sequelae in this disease.

The CF mice have also been tested in this model for their ability to clear P. aeruginosa (102). This result is apparently in keeping with other observations using the agar-bead chronic infection model (106, 107) or another aerosol infection model (108). These mice presented two extremes: either clearing or not clearing P. aeruginosa. This finding seems to be associated with variations in mouse body weight and nutritional status. When CFTRmlUNC-/- mice had their intestinal defect corrected by a functional human CFTR gene expressed from a rat intestinal fatty acid-binding protein gene promoter CFTRmlUNC-/- (FABP-hCFTR mouse; ref. 92), P. aeruginosa was efficiently cleared from the lung and variability was no longer observed. While these observations may suggest that repairing the CFTR defect in the intestinal tract improves lung defense against P. aeruginosa, they also show that CF transgenic mice may be incapable of clearing Pseudomonas lung infections under certain conditions.

Recently, we have tested the role of malnutrition in host pulmonary defenses against P. aeruginosa colonizations in a group of C57BL/6J mice which was first induced with protein energy malnutrition (PEM) and then exposed to P. aeruginosa aerosol (102). PEM resulted in a 11-fold increase of P. aeruginosa survival in the lungs of the C57BL/6J mice. PEM also contributed to excessive inflammation upon chronic infections with P. aeruginosa. The repeatedly infected malnourished mice did not produce IL-10 in their lungs. In addition to increased levels of proinflammatory cytokines and neutrophil infiltration, another CF hallmark is a low level of the major anti-inflammatory cytokine IL-10 in the bronchio-alveolar fluid (105). Using a model of a repeated exposure with P. aeruginosa (101), we observed significant amounts of IL-10 production in the well-nourished mice 22 days following the initiation of the regimen of repeated exposures. In contrast, the malnourished animals had no detectable IL-10. These results demonstrate that malnutrition compromises pulmonary defenses against P. aeruginosa colonization and is conducive to excessive inflammation in response to P. aeruginosa infection, resembling the situation in CF. Furthermore, neutrophil infiltration in the lungs of malnourished animals did not result in increased bacterial lung clearance and instead was a correlate of an unproductive inflammatory response. In two separate reports using a sepsis model induced by P. aeruginosa (109) and a chronic infection model with Pseudomonas-laden agar beads (110), respectively, increased neutrophil infiltration and increased bacterial load in the lungs were detected at the same time. These results suggest that neutrophils under these conditions (e.g., PEM, sepsis and chronic infection) may not be fully activated or functional in the process of eliminating Pseudomonas from the lungs. Therefore, neutrophil-mediated bactericidal mechanisms need to be further investigated since pulmonary alveolar macrophages have recently been shown to play a marginal role in defense against P. aeruginosa infections in mice (111).


The major characteristic of chronic lung infections in CF is the persistence of bacterial pathogens despite excessive immune response from the host (112). The normal innate pulmonary defense systems involve mucociliary clearance and cough, phagocytes and antimicrobial factors such as defensins (113). In normal individuals, an effective inflammatory response involving proinflammatory cytokines is needed immediately after exposure to P. aeruginosa. However, the successful initial colonization of P. aeruginosa in the CF lungs suggests that the innate immunity that is required for Pseudomonas clearance is defective in CF. When this fails, biofilm formation, accompanied by excessive inflammation, occurs resulting in chronic infection. Chronic pulmonary inflammation, caused by excessive neutrophil infiltration and an unproductive immune response, is one of the major clinical manifestations in CF. The CF patients apparently have the ability to elicit humoral and cell-mediated immune responses. The phagocytic cells of CF patients appear to lack any major functional abnormalities (44). Furthermore, CF patients are able to mount an antibody response since the proteinaceous antigens of P. aeruginosa are processed by antigen presenting cells and presented to T-cells as evidenced by the presence of anti-toxin (112) and more recently, anti-type-III-protein antibodies (114) in the serum of CF patients. The problem encountered in combating P. aeruginosa persistent infections is due to the deficiency of an effective removal system of MEP enclosed microcolonies of P. aeruginosa and therefore causing increased and prolonged host inflammatory responses (115). The antibody-bacterial complex aggregates, which are too large to be phagocytized, could act as foci for "frustrated phagocytosis" (116). Fc-receptor mediated degranulation and oxidative burst due to the presence of continuous infiltration of neutrophils occur, resulting in excessive inflammation and tissue destruction.

Biofilm formation, particularly conversion to the mucoid phenotype leading to development of mature biofilms, impairs the normal immune response process in CF patients. Alginate is immunogenic, and can act as an efficient polyclonal B-cell activator (117) leading to a clinical condition mainly present in older CF patients: hyperimmunoglobulinemia (44). Another peculiar property of alginate is that excessive amounts in the experimental animals induces production of non-protective and low opsonizing antibodies (45). Using serum from a patient undergoing an exacerbation, it was demonstrated by cross immunoelectrophoresis that the serum recognized more than 30 distinct P. aeruginosa antigens (118). In contrast, serum from a patient in remission, who had been infected for 16 years, only recognized five antigens (119). This provided prima facie evidence of masking P. aeruginosa antigens by biofilm-forming bacteria.

The seminal work performed to establish the basic concept for P. aeruginosa biofilms was done in the early 1980s. Using direct electron microscopic analysis of post-mortem lung tissues from CF patients, Lam et al. (118) demonstrated that P. aeruginosa in CF lungs form aggregates or microcolonies (figure 4). Excessive amounts of alginate surrounding microcolonies during the course of chronic infections in CF directly impair antigen presentation. Antibody response to iron-regulated outer membrane proteins (IROMPs) in CF patients does not appear early in the infection and is apparently associated with the advanced stage of the disease (120). The rough LPS mutants of P. aeruginosa emerge during the course of chronic infections in CF patients who have a high titer of anti-LPS antibodies, but the immune systems of CF patients fail to eradicate the serum-sensitive mucoid variant P. aeruginosa infections (44). Efforts for vaccine development have been mainly focused on the following candidates: O-polysaccharide, toxins, flagella, outer membrane proteins and alginate (121). Though some candidates are promising, an effective anti-Pseudomonas vaccine is still not available. Recently, it has been reported that a DNA vaccine carrying oprF allows the immunized mice to produce a significantly higher level of opsonic IgG1 antibody, confering protection in these mice (122). Genetic vaccines combined with molecular adjuvants may offer a new approach for future development of vaccines against P. aeruginosa infections in CF.


Recent completion of the entire PAO1 genomic sequence accompanied by discoveries of genomic islands from clinical isolates spurs further investigation of the genetic diversity in P. aeruginosa. Some of the relevant questions to now address include i) the number of islands present per genome; ii) the relationship between the islands and diversity; iii) identification of any CF- and/or other disease-specific islands; and iv) elucidation of specific virulence roles for the islands including their possible involvement in biofilm formation. Some of the challenging topics related to biofilm research include i) identification and characterization of new adhesins, and ii) control of biofilm formation by quorum sensing and other global regulators. To establish a relationship between in vitro and in vivo biofilm formation, it is necessary to evaluate biofilm formation defective mutants in a proper animal model. A good CF infection mouse model will allow us to reproduce the chronic infection process, i.e., from initial nonmucoid cell colonization to in vivo mucoidy conversion leading to development of mature biofilms coupled with excessive neutrophilic inflammation and inflammatory cytokine profiles similar to what is seen in human CF. Development of a true CF disease animal model and elucidation of the molecular mechanisms underlying the transition to the persistent infection phenotypes in this organism could lead to novel therapeutic strategies against chronic P. aeruginosa lung infections in CF.


We thank D. Speert, F. Ausubel, P. Phibbs, and C. Somerville for providing the clinical CF, burn and environmental isolates used in this study; T. W. Fenger for sharing the PFGE apparatus. This work is supported by an operating grant to H.Y. from the Joan C. Edwards School of Medicine at Marshall University.


1. Costerton, J. W., P. S. Stewart, & E. P. Greenberg: Bacterial biofilms: a common cause of persistent infections. Science 284, 1318-1322 (1999)

2. Collins, F. S.: Cystic fibrosis: molecular biology and therapeutic implications. Science 256, 774-779 (1992)

3. Wine, J. J.: The genesis of cystic fibrosis lung disease. Journal of Clinical Investigation 103, 309-312 (1999)

4. Choi, J. Y., D. Muallem, K. Kiselyov, M. G. Lee, P. J. Thomas, & S. Muallem: Aberrant CFTR-dependent HCO-3 transport in mutations associated with cystic fibrosis. Nature 410, 94-97 (2001)

5. Tomashefski Jr., J. F., C. R. Abramowsky, & B. B. Dahms: The pathology of cystic fibrosis. In: Lung Biology in Health and Disease. Eds: Davis, P. B., Marcel Dekker, Inc., New York p. 435-489 (1993)

6. Welsh, M. J., B. W. Ramsey, F. Accurso, & G. R. Cutting: Cystic fibrosis. In: The metabolic & molecular bases of inherited disease. Eds: Valle, D., McGraw-Hill, New York p. 5121-5188 (2001)

7. Pencharz, P., & P. Durie: Nutritional management of cystic fibrosis. Ann Rev Nutr 13, 111-136 (1993)

8. Deretic, V.: Pseudomonas aeruginosa infections. In: Persistent bacterial infections. Eds: Cunningham-Rundles, S., ASM Press, Washington, DC p. 305-326 (2000)

9. Govan, J. R. W., & V. Deretic: Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 60, 539-574 (1996)

10. Konstan, M. W., & M. Berger: Infection and inflammation of the lung in cystic fibrosis. In: Cystic fibrosis. Eds: Davis, P. B., Marcel Dekker, Inc., New York p. 219-276 (1993)

11. Burns, J. L., R. L. Gibson, S. McNamara, D. Yim, J. Emerson, M. Rosenfeld, P. Hiatt, K. McCoy, R. Castile, A. L. Smith, & B. W. Ramsey: Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 183, 444-452 (2001)

12. Pier, G. B.: Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc Natl Acad Sci USA 97, 8822-8828 (2000)

13. Bonfield, T. L., J. R. Panuska, M. W. Konstan, K. A. Hillard, J. B. Hillard, H. Ghnaim, & M. Berger: Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 152, 2111-2118 (1995)

14. Goldman, M. J., G. M. Anderson, E. D. Stolzenberg, U. P. Kari, M. Zasloff, & J. M. Wilson: Human b-Defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 88, 553-560 (1997)

15. Khan, T. Z., J. S. Wagener, T. Bost, J. Martinez, F. J. Accurso, & D. W. H. Riches: Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 151, 1075-1082 (1995)

16. Pier, G. B., M. Grout, T. S. Zaidi, J. C. Olsen, L. G. Johnson, J. R. Yankaska, & J. B. Goldberg: Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. Science 271, 64-67 (1996)

17. Smith, J. J., S. M. Travis, E. P. Greenberg, & M. J. Welsh: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell 85, 1-20 (1996)

18. Zar, H., L. Saiman, L. Quittell, & A. Prince: Binding of Pseudomonas aeruginosa to respiratory epithelial cells from patients with various mutations in the cystic fibrosis transmembrane regulator. J Pediatr 126, 230-233 (1995)

19. Schroeder, T. H., T. Zaidi, & G. B. Pier: Lack of adherence of clinical isolates of Pseudomonas aeruginosa to asialo-GM1 on epithelial cells. Infect Immun 69, 719-729 (2001)

20. Biwersi, J., & A. S. Verkman: Functions of CFTR other than as a plasma membrane chloride channel. In: Cystic fibrosis-current topics, Vol 2. Eds: Widdicombe, J. H., John Wiley & Sons Ltd, Chichester p. 155-171 (1994).

21. Tirouvanziam, R., S. de Bentzmann, C. Hubeau, J. Hinnrasky, J. Jacquot, B. Peault, & E. Puchelle: Inflammation and infection in naive human cystic fibrosis airway grafts. Am J Respir Cell Mol Biol 23, 121-127 (2000)

22. Wilson, R., & R. B. Dowling: Pseudomonas aeruginosa and other related species. Thorax 53, 213-219 (1998)

23. Stover, C. K., X. Q. Pham, A. L. Erwin, S. D. Mizoguchi, P. Warrener, M. J. Hickey, F. S. Brinkman, W. O. Hufnagle, D. J. Kowalik, M. Lagrou, R. L. Garber, L. Goltry, E. Tolentino, S. Westbrock-Wadman, Y. Yuan, L. L. Brody, S. N. Coulter, K. R. Folger, A. Kas, K. Larbig, R. Lim, K. Smith, D. Spencer, G. K. Wong, Z. Wu, & I. T. Paulsen: Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 406, 959-64 (2000)

24. Holloway, B. W.: Genetic recombination in Pseudomonas aeruginosa. J Gen Microbiol 13, 572-581 (1955)

25. Lam, J., R. Chan, K. Lam, & J. W. Costerton: Production of mucoid microcolonies by Pseudomonas aeruginosa within infected lungs in cystic fibrosis. Infect Immun 28, 546-556 (1980)

26. Singh, P. K., A. L. Schaefer, M. R. Parsek, T. O. Moninger, M. J. Welsh, & E. P. Greenberg: Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 407, 762-764 (2000)

27. Pratt, L. A., & R. Kolter: Genetic analysis of bacterial biofilm formation. Current opinion in microbiology 2, 598-603 (1999)

28. Costerton, J. W., K. Cheng, G. G. Geesey, T. I. Ladd, J. C. Nickel, M. Dasgupta, & T. J. Marrie: Bacterial biofilms in nature and disease. Ann Rev Microbiol 41, 435-464 (1987)

29. Stickler, D.: Biofilms. Curr Opin Microbiol 2, 270-5 (1999)

30. O'Toole, G. A., & R. Kolter: Flagellar and twiching motilities are necessary for Pseudomonas aeruginosa biofilm development. Mol Microbiol 30, 295-304 (1998)

31. Deziel, E., Y. Comeau, & R. Villemur: Initiation of biofilm formation by Pseudomonas aeruginosa 57RP correlates with emergence of hyperpiliated and highly adherent phenotypic variants deficient in swimming, swarming, and twitching motilities. J Bacteriol 183, 1195-1204 (2001)

32. Vidal, O., R. Longin, C. Prigent-Combaret, C. Dorel, M. Hooreman, & P. Lejeune: Isolation of an Escherichia coli K-12 mutant strain able to form biofilms on insert surfaces: Involvement of a new ompR allele that increases curli expression. J Bacteriol 180, 2442-2449 (1998)

33. Vallet, I., J. W. Olson, S. Lory, A. Lazdunski, & A. Filloux: The chaperone/usher pathways of Pseudomonas aeruginosa: identification of fimbrial gene clusters (cup) and their involvement in biofilm formation. Proc Natl Acad Sci U S A 98, 6911-6 (2001)

34. O'Toole, G. A., K. A. Gibbs, P. W. Hager, P. V. Phibbs, Jr., & R. Kolter: The global carbon metabolism regulator Crc is a component of a signal transduction pathway required for biofilm development by Pseudomonas aeruginosa. J Bacteriol 182, 425-31 (2000)

35. Rashid, M. H., K. Rumbaugh, L. Passador, D. G. Davies, N. H. Abdul, B. H. Iglewski, & A. Kornberg: Polyphosphate kinase is essential for biofilm development, quorum sensing, and virulence of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 97, 9636-9641 (2000)

36. Parkins, M. D., H. Ceri, & D. G. Storey: Pseudomonas aeruginosa GacA, a factor in multihost virulence, is also essential for biofilm formation. Mol Microbiol 40, 1215-26 (2001)

37. Pearson, J. P., C. Van Delden, & B. H. Iglewski: Roles of Pseudomonas aeruginosa las and rhl quorum-sensing systems in control of elastase and rhamnolipid biosynthesis genes. J Bacteriol 179, 5756-5767 (1997)

38. Parsek, M. R., & E. P. Greenberg: Acyl-homeserine lactone quorum sensing in Gram-negative bacteria: A signaling mechanism involved in associations with higher organisms. Proc Natl Acad Sci USA 97, 8789-8793 (2000)

39. Parsek, M. R., D. L. Val, B. L. Hanzelka, J. E. J. Cronan, & E. P. Greenberg: Acyl homoserine-lactone quorum-sensing signal generation. Proc Natl Acad Sci USA 1999, 4360-4365 (1999)

40. Davies, D. G., M. R. Parsek, J. P. Pearson, B. H. Iglewski, J. W. Costerton, & E. P. Greenberg: The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280, 295-298 (1998)

41. Nivens, D. E., D. E. Ohman, J. Williams, & M. J. Franklin: Role of aliginate and its O acetylation in formation of Pseudomonas aeruginosa microcolonies and biofilms. J Bacteriol 183, 1047-1057 (2001)

42. Martin, D. W., M. J. Schurr, M. H. Mudd, J. R. W. Govan, B. W. Holloway, & V. Deretic: Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients. Proc Natl Acad Sci USA 90, 8377-8381 (1993)

43. Mathee, K., O. Ciofu, C. Sternberg, P. Lindum, J. I. A. Campbell, P. Jensen, A. H. Johnsen, M. Givskow, D. E. Ohman, S. Molin, N. Hoiby, & A. Kharazmi: Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. Microbiology 145, 1349-1357 (1999)

44. Speert, D. P.: Pseudomonas aeruginosa infections in patients with cystic fibrosis. In: Pseudomonas aeruginosa infections and treatment. Eds: Smith, R. P., Marcel Dekker, Inc., New York p. 183-236 (1994)

45. Pier, G. B., G. J. Small, & H. B. Warren: Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections. Science 249, 537-540 (1990)

46. Parad, R. B., C. J. Gerard, D. Zurakowski, D. P. Nichols, & G. B. Pier: Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun 67, 4744-4750 (1999)

47. Demko, C. A., P. J. Byard, & P. B. Davis: Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 48, 1041-9 (1995)

48. Yu, H., M. J. Schurr, J. C. Boucher, J. M. Martinez-Salazar, D. W. Martin, & V. Deretic: Molecular mechanism of conversion to mucoidy in Pseudomonas aeruginosa. In: Molecular biology of pseudomonads. Eds: Haas, D., ASM Press, Washington, D.C. p. 384-397 (1996)

49. Yu, H., M. J. Schurr, & V. Deretic: Functional equivalence of Escherichia coli sE and Pseudomonas aeruginosa AlgU: E. coli rpoE restores mucoidy and reduces sensitivity to reactive oxygen intermediates in algU mutants of P. aeruginosa. J Bacteriol 177, 3259-3268 (1995)

50. Garrett, E. S., D. Perlegas, & D. J. Wozniak: Negative control of flagellum synthesis in Pseudomonas aeruginosa is modulated by the alternative sigma factor AlgT. J Bacteriol 181, 7401-7404 (1999)

51. Head, N. E., N. D. Noureddine, & H. Yu. (Unpublished)

52. Yu, H., J. C. Boucher, N. S. Hibler, & V. Deretic: Virulence properties of Pseudomonas aeruginosa lacking the extreme-stress sigma factor AlgU (sE). Infect Immun 64, 2774-2781 (1996)

53. Hanna, S. L., N. E. Sherman, M. T. Kinter, & J. B. Goldberg: Comparison of proteins expressed by Pseudomonas aeruginosa strains representing initial and chronic isolates from a cystic fibrosis patient: an analysis by 2-D gel electrophoresis and capillary column liquid chromatography-tandem mass spectrometry. Microbiology 146, 2495-508 (2000)

54. Malhotra, S., L. A. Silo-Suh, K. Mathee, & D. E. Ohman: Proteome analysis of the effect of mucoid conversion on global protein expression in Pseudomonas aeruginosa strain PAO1 shows induction of the disulfide bond isomerase, DsbA. J Bacteriol 182, 6999-7006 (2000)

55. Harder, J., U. Meyer-Hoffert, L. M. Teran, L. Schwichtenberg, J. Bartels, S. Maune, & J. M. Schroder: Mucoid Pseudomonas aeruginosa, TNF-a, and IL-1b, but not IL-6, induces human b-defensin-2 in respiratory epithelia. Am J Respir Cell Mol Biol 22, 714-721 (2000)

56. Boucher, J. C., M. J. Schurr, & V. Deretic: Dual regulation of mucoidy in Pseudomonas aeruginosa and sigma factor antagonism. Mol Microbiol 36, 341-351 (2000)

57. Kiewitz, C., & B. Tummler: Sequence diversity of Pseudomonas aeruginosa: impact on population structure and genome evolution. J Bacteriol 182, 3125-35 (2000)

58. Romling, U., J. Grelpel, & B. Tummler: Gradients of genomic diversity in the Pseudomonas aeruginosa chromosome. Mol Microbiol 17, 323-332 (1995)

59. Romling, U., J. Wingender, H. Muller, & B. Tummler: A major Pseudomonas aeruginosa clone common to patients and aquatic habitats. Appl Environ Microbiol 60, 1734-8 (1994)

60. Romling, U., T. Heuer, & B. Tummler: Bacterial genome analysis by pulsed field gel electrophoresis techniques. In: Advances in electrophoresis. Eds: Radola, VCH Publishers, Inc., Weinheim, Germany p. 353-406 (1994)

61. Ruimy, R., E. Genauzeau, C. Barnabe, A. Beaulieu, M. Tibayrenc, & A. Andremont: Genetic diversity of Pseudomonas aeruginosa strains isolated from ventilated patients with nosocomial pneumonia, cancer patients with bacteremia, and environmental water. Infect Immun 69, 584-588 (2001)

62. Holloway, B. W., U. Romling, & B. Tummler: Genomic mapping of Pseudomonas aeruginosa PAO. Microbiology 140, 2907-2929 (1994)

63. Liao, X., I. Charlebois, C. Ouellet, M. J. Morency, K. Dewar, J. Lightfoot, J. Foster, R. Siehnel, H. Schweizer, J. S. Lam, R. E. W. Hancock, & R. C. Levesque: Physical mapping of 32 genetic markers on the Pseudomonas aeruginosa PAO1 chromosome. Microbiology 142, 79-86 (1996)

64. Ratnaningsih, E. S., S. Dharmsthiti, V. Krishnapillai, A. Morgan, M. Sinclair, & B. W. Holloway: A combined physical and genetic map of Pseudomonas aeruginosa PAO. J Gen Microbiol 136, 2351-2357 (1990)

65. Shortridge, V. D., M. L. Pato, A. I. Vasil, & M. L. Vasil: Physical mapping of virulence-associated genes in Pseudomonas aeruginosa by transverse alternating-field electrophoresis. Infect Immun 59, 3596-3603 (1991)

66. Schmidt, K. D., B. Tummler, & U. Romling: Comparative genome mapping of Pseudomonas aeruginosa PAO with P. aeruginosa C, which belongs to a major clone in cystic fibrosis patients and aquatic habitats. J Bacteriol 178, 85-93 (1996)

67. Schmidt, K. D., T. Schmidt-Rose, U. Romling, & B. Tummler: Differential genome analysis of bacterial by genomic substractive hybridization and pulsed field gel electrophoresis. Electrophoresis 19, 509-514 (1998)

68. Hla, S. W., K. P. Hui, W. C. Tan, & B. Ho: Genome macrorestriction analysis of sequential Pseudomonas aeruginosa isolates from bronchiectasis patients without cystic fibrosis. J Clin Microbiol 34, 575-578 (1996)

69. Matsuda, J., Y. Hirakata, F. Iori, C. Mochida, Y. Ozaki, M. Nakano, K. Izumikawa, T. Yamaguchi, R. Yoshida, Y. Miyazaki, S. Maesaki, K. Tomono, Y. Yamada, S. Kohno, & S. Kamihira: Genetic relationship between blood and nonblood isolates from bacteremic patients determined by pulsed-field gel electrophoresis. J Clin Microbiol 36, 3081-3084 (1998)

70. Pujana, I., L. Gallego, M. F. Lopez, J. Canduela, & R. Cisterna: Epiemiological analysis of sequential Pseudomonas aeruginosa isolates from chronic bronchiectasis patients without cystic fibrosis. J Clin Microbiol 37, 2071-2073 (1999)

71. Mahenthiralingam, E., M. E. Campbell, J. Foster, J. S. Lam, & D. P. Speert: Random amplified polymorphic DNA typing of Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis. J Clin Microbiol 34, 1129-1135 (1996)

72. Render, N., U. Romling, H. Verbrugh, & A. Van Belkum: Comparative typing of Pseudomonas aeruginosa by random amplification of polymorphic DNA or pulsed-field gel electrophoresis of DNA macrorestrition fragments. J Clin Microbiol 34, 3190-3195 (1996)

73. Head, N. E., & H. Yu. (Unpublished data)

74. Oliver, A., R. Canton, P. Campo, F. Baquero, & J. Blazquez: High Frequency of Hypermutable Pseudomonas aeruginosa in Cystic Fibrosis Lung Infection. Science 288, 1251-1253 (2000)

75. Spiers, A. J., A. Buckling, & P. B. Rainey: The causes of Pseudomonas diversity. Microbiology 146, 2345-2350 (2000)

76. Hacker, J., & J. B. Kaper: The concept of pathogenicity islands. In: Pathogenicity islands and other mobile virulence elements. Eds: Hacker, J., ASM Press, Washington, DC p. 1-11 (1999)

77. Arora, S. K., M. Bangera, S. Lory, & R. Ramphal: A genomic island in Pseudomonas aeruginosa carries the determinants of flagellin glycosylation. Proc Natl Acad Sci U S A 98, 9342-7 (2001).

78. Liang, X., X. T. Pham, M. V. Olson, & S. Lory: Identification of a Genomic Island Present in the Majority of Pathogenic Isolates of Pseudomonas aeruginosa. J Bacteriol 183, 843-853 (2001)

79. Wilderman, P. J., A. I. Vasil, Z. Johnson, & M. L. Vasil: Genetic and biochemical analysis of a eukaryotic-like phopholipase D of Pseudomonas aeruginosa suggest horizontal acquisition and a role for persistence in a chronic pulmonary infection model. Mol Microbiol 39, 291-303 (2001)

80. Kropinski, A. M.: Sequence of the genome of the temperate, serotype-converting, Pseudomonas aeruginosa bacteriophage D3. J Bacteriol 182, 6066-6074 (2000)

81. Mahajan-Miklos, S., M. W. Tan, L. G. Rahme, & F. M. Ausubel: Molecular mechanisms of bacterial virulence elucidated using a Pseudomonas aeruginosa-Caenorhabditis elegans pathogenesis model. Cell 96, 47-56 (1999)

82. Tan, M. W., S. Mahajan-Miklos, & F. M. Ausubel: Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. Proc Natl Acad Sci U S A 96, 715-20 (1999)

83. Tan, M. W., L. G. Rahme, J. A. Sternberg, R. G. Tompkins, & F. M. Ausubel: Pseudomonas aeruginosa killing of Caenorhabditis elegans used to identify P. aeruginosa virulence factors. Proc Natl Acad Sci U S A 96, 2408-13 (1999)

84. Perna, N. T., G. Plunkett, V. Burland, B. Mau, J. D. Glasner, D. J. Rose, G. F. Mayhew, P. E. Evans, J. Gregor, H. A. Kirkpatrick, G. Posfai, J. Hackett, S. Klink, A. Boutin, Y. Shao, L. Miller, E. J. Grotbeck, N. W. Davis, A. Lim, E. T. Dimalanta, K. D. Potamousis, J. Apodaca, T. S. Anantharaman, J. Lin, G. Yen, D. C. Schwartz, R. A. Welch, & F. R. Blattner: Genome sequence of enterohaemorrhagic Escherichia coli O157:H7. Nature 409, 529-533 (2001)

85. Brimer, C. D., & T. C. Montie: Cloning and comparison of fliC genes and identification of glycosylation in the flagellin of Pseudomonas aeruginosa a-type strains. J Bacteriol 180, 3209-17 (1998)

86. Colledge, W., R. Ratcliffe, D. Foster, R. Williamson, & M. J. Evans: Cystic fibrosis mouse with intestinal obstruction. Lancet 340, 680 (1992)

87. Colledge, W. H., B. S. Abella, K. W. Southern, R. Ratcliff, C. Jiang, S. H. Cheng, L. J. MacVinish, J. R. Anderson, A. W. Cuthbert, & M. J. Evans: Generation and characterization of a D508 cystic fibrosis mouse model. Nat Genet 10, 445-452 (1995)

88. Dorin, J. R., P. Dickinson, E. W. F. W. Alton, S. N. Smith, D. M. Geddes, B. J. Stevenson, W. L. Kimber, S. Fleming, A. R. Clarke, M. L. Hooper, L. Anderson, R. S. P. Beddington, & D. J. Porteous: Cystic fibrosis in the mouse by target insertional mutagenesis. Nature 359, 211-215 (1992)

89. O'Neal, W. K., P. Hasty, P. B. McCray, B. Casey, J. Rivera-Perez, M. J. Welsh, A. L. Beaudet, & A. Bradley: A severe phenotype in mice with a duplication of exon 3 in the cystic fibrosis locus. Hum Mol Genet 2, 1561-1569 (1993)

90. Snouwaert, J. N., K. K. Brigman, A. M. Latour, N. N. Malouf, R. C. Boucher, O. Smithies, & B. H. Koller: An animal model for cystic fibrosis made by gene targeting. Science 257, 1083-1088 (1992)

91. van Doorninck, J. H., P. J. French, E. Verbeek, R. H. Peters, H. Morreau, J. Bijman, & B. J. Scholte: A mouse model for the cystic fibrosis delta F508 mutation. EMBO J 14, 4403-4411 (1995)

92. Zeiher, B. G., E. Eichwald, J. Zabner, J. J. Smith, A. P. Puga, P. B. McCray, M. R. Capecchi, M. J. Welsh, & K. R. Thomas: A mouse model for the delta F508 allele of cystic fibrosis. J Clin Invest 96, 2051-2064 (1995)

93. Zhou, L., C. R. Dey, S. E. Wert, M. D. DuVall, R. A. Frizzell, & J. A. Whitsett: Correction of lethal intestinal defect in a mouse model of cystic fibrosis by human CFTR. Science 266, 1705-1708 (1994)

94. Clarke, L. L., B. R. Grubb, J. R. Yankaskas, C. U. Cotton, A. McKenzie, & R. C. Boucher: Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ level disease in CFTR(-?-) mice. Proc Natl Acad Sci USA 91, 479-483 (1994)

95. Cowley, E. A., K. Govindaraju, C. Guilbault, D. Radzioch, & D. H. Eidelman: Airway surface liquid composition in mice. Am J Physiol Lung Cell Mol Physiol 278, L1213-L1220 (2000)

96. Zahm, J. M., S. Baconnais, D. J. Davidson, S. Webb, J. Dorin, N. Bonnet, G. Balossier, & E. Puchelle: X-ray microanalysis of airway surface liquid collected in cystic fibrosis mice. Am J Physiol Lung Cell Mol Physiol 281, L309-13 (2001)

97. Verkman, A. S.: Lung disease in cystic fibrosis: is airway surface liquid composition abnormal? Am J Physiol Lung Cell Mol Physiol 281, L306-8 (2001)

98. Kent, G., R. Iles, C. E. Bear, L. Huan, U. Griesenbach, C. McKerlie, H. Frndova, C. Ackerley, D. Gosselin, D. Razioch, H. O'Brodovich, L. Tsui, M. Buchwald, & A. K. Tanswell: Lung disease in mice with cystic fibrosis. J Clin Invest 100, 3060-3069 (1997)

99. Yu, H., J. C. Boucher, & V. Deretic: Molecular analysis of Pseudomonas aeruginosa virulence. In: Methods in microbiology: bacterial pathogenesis. Eds: Salmond, G. P. C., Academic Press, London p. 383-393 (1998)

100. Boucher, J. C., H. Yu, M. H. Mudd, & V. Deretic: Mucoid Pseudomonas aeruginosa in cystic fibrosis: characterization of muc mutations in clinical isolates and analysis of clearance in a mouse model of respiratory infection. Infect Immun 65, 3838-3846 (1997)

101. Yu, H., M. Hanes, C. E. Chrisp, J. C. Boucher, & V. Deretic: Microbial pathogenesis in cystic fibrosis: pulmonary clearance of mucoid Pseudomonas aeruginosa and inflammation in a mouse model of repeated respiratory challenge. Infect Immun 66, 280-288 (1998)

102. Yu, H., S. Z. Nasr, & V. Deretic: Innate lung defenses and compromised Pseudomonas aeruginosa clearance in the malnourished mouse model of respiratory infections in cystic fibrosis. Infect Immun 68, 2142-2147 (2000)

103. Orme, I. M., & F. M. Collins: Mouse model of tuberculosis. In: Tuberculosis: pathogenesis, protection and control. Eds: Bloom, B. R., ASM Press, Washington, D.C. p. 113-134 (1994)

104. Chmiel, J. F., M. W. Konstan, J. E. Knesebeck, J. B. Hilliard, T. L. Bonfield, D. V. Dawson, & M. Berger: IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice. Am J Respir Crit Care Med 160, 2040-2047 (1999)

105. Bonfield, T. L., M. W. Konstan, P. Burfeind, J. R. Panuska, J. B. Hilliard, & M. Berger: Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol 13, 257-261 (1995)

106. Gosselin, D., M. M. Stevenson, E. A. Cowley, U. Griesenbach, D. H. Eidelman, M. Boule, M. F. Tam, G. Kent, E. Skamene, L. C. Tsui, & D. Radzioch: Impaired ability of Cftr knockout mice to control lung infection with Pseudomonas aeruginosa. Am J Respir Crit Care Med 157, 1253-1262 (1998)

107. van Heeckeren, A., R. Walenga, M. W. Konstan, T. Bonfield, P. B. Davis, & T. Ferkol: Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with Pseudomonas aeruginosa. J Clin Invest 100, 2810-2815 (1997)

108. McCray Jr., P. B., J. Zabner, H. P. Jia, M. J. Welsh, & P. S. Thorne: Efficient killing of inhaled bacteria in delta F508 mice: role of airway surface liquid composition. Am J Physiol Lung Cell Mol Physiol 21, L183-L190 (1999)

109. Steinhauser, M. L., C. M. Hogaboam, S. L. Kunkel, N. W. Lukacs, R. M. Strieter, & T. J. Standiford: IL-10 is a major mediator of sepsis-induced impairment in lung antibacterial host defense. J Immunol 162, 392-399 (1999)

110. van Heeckeren, A. M., J. Tscheikuna, R. Walenga, M. W. Konstan, P. B. Davis, B. Erokwu, M. A. Haxhiu, & T. Ferkol: Effect of Pseudomonas aeruginosa infection on weight loss, lung mechanics, and cytokines in mice. Am J Respir Crit Care Med 161, 271-279 (2000)

111. Cheung, D. O. Y., K. Halsey, & D. P. Speert: Role of pulmonary alveolar macrophages in defense of the lung against Pseudomonas aeruginosa. Infect Immun 68, 4585-4592 (2000)

112. Hoiby, N., A. Fomsgaard, E. T. Jensen, H. K. Johansen, G. Kronborg, S. S. Pedersen, T. Pressler, & A. Kharazmi: The immune response to bacterial biofilms. In: Microbial biofilms. Eds: Costerton, J. W., Cambrige University Press, Cambridge p. 233-250 (1995)

113. Travis, S. M., P. K. Singh, & M. J. Welsh: Antimicrbial peptides and proteins in the innate defense of the airway surface. Current opinion in immunology 13, 89-95 (2001)

114. Moss, J., M. E. Ehrmantraut, B. D. Banwart, D. W. Frank, & J. T. Barbieri: Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus. Infect Immun 69, 1185-1188 (2001)

115. Muhlebach, M. S., P. W. Stewart, M. W. Leigh, & T. L. Noah: Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 160, 186-191 (1999)

116. Govan, J. R., & G. S. Harris: Pseudomonas aeruginosa and cystic fibrosis: unusual bacterial adaptation and pathogenesis. Microbiol Sci 3, 302-308 (1986)

117. Daley, L., G. B. Pier, J. D. Liporace, & D. D. Eardley: Polyclonal B cell stimulation and interleukin 1 induction by the mucoid exopolysaccharide of Pseudomonas aeruginosa associated with cystic fibrosis. J Immunol 134, 3089-3093 (1986)

118. Lam, J. S., L. M. Mutharia, R. E. W. Hancock, N. Hoiby, K. Lam, B. L., & J. W. Costerton: Immunogenicity of Pseudomonas aeruginosa outer membrane antigens examined by crossed immunoelectrophoresis. Infect Immun 42, 88-98 (1983)

119. Costerton, J. W., T. J. Marrie, & J. C. Nickel: The role of bacterial glycocalyx and the biofilm mode of growth. Roche seminars of bacteria (1986)

120. Shand, G. H., S. S. Pedersen, M. R. W. Brown, & N. Hoiby: Serum antibodies to Pseudomonas aeruginosa outer-membrane proteins and iron-regulated membrane proteins at different stages of chronic cystic fibrosis lung infection. J Med Microbiol 34, 203-212 (1991)

121. Cryz, S. J.: Vaccines, immunoglobulins, and monoclonal antibodies for the prevention and treatment of Pseudomonas aeruginosa infections. In: Pseudomonas aeruginosa: Infection and treatment. Eds: Smith, R. P., Marcel Dekker, New York, NY p. 519-545 (1994)

122. Price, B. M., D. R. Galloway, N. R. Baker, L. B. Gilleland, J. Staczek, & H. E. Gilleland: Protection against Pseudomoans aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa. Infect Immun 69, 3510-3515 (2001)

Key Words: Cystic Fibrosis; Chronic Infections; Pseudomonas aeruginosa: Biofilm; Mucoidy; PFGE; Genomic Diversity; Genomic Island; Aerosol Infection; Mouse Model, Review

Send Correspondence to: Dr. Hongwei Yu, Department of Microbiology, Immunology and Molecular Genetics, Joan C. Edwards School of Medicine at Marshall University, 1542 Spring Valley Drive, Huntington, WV 25704, Tel: 304-696-7356, Fax: 304-696-7207, E-mail: Yuh@marshall.edu